Safety and Efficacy of CMD03 CAR T Cell in Children With Relapse or Refractory Solid Tumors

Официальное название

Safety and Efficacy of B7H3 With IL-7 Receptor Alpha Signaling Chimeric Antigen Receptor T Cell (CMD03) in Relapse and Refractory Pediatric Solid Tumors

Обзор

A Phase 1 clinical trial to evaluate the safety and early efficacy of CAR T-cells with IL-7Ra signal targeting B7H3 in children with solid tumors patients after complete standard treatments.

Подробное описание

Currently, treatment options for pediatric solid tumors that have recurred or are unresponsive to standard treatments are limited. These cancers often do not respond to other chemotherapy drugs or targeted therapies available today. As a result, there is currently no effective treatment for pediatric solid tumors that have recurred or are unresponsive to standard treatments.

At present, immunotherapy for cancer treatment is being developed. This involves genetically modifying the patient\'s immune cells to target specific cancer cells, known as CAR T cells. This approach is used to treat recurrent or unresponsive solid tumors and brain cancers that do not respond to standard treatments.

The research aims to study the efficacy and safety of treating pediatric patients with recurrent or unresponsive solid tumors using a type of immunotherapy called CAR T cells. These cells are engineered to express a chimeric antigen receptor that includes an interleukin-7 receptor alpha signaling domain and targets the B7-H3 antigen on tumor surfaces. This research is the first of its kind conducted on Thai patients. The research team expects this treatment to be highly safe and effective in controlling cancer.

Вмешательства

• Биопрепарат B7H3-IL7Ra CAR-T cells
  Autologous T cells lentiviral transduced to express a B7H3-specific chimeric antigen receptor (CAR) with the addition of an IL-7 receptor alpha signaling domain, administered via central venous access catheter after lymphodepletion

Первичные конечные точки

• Safety and tolerability of B7H3-IL7Ra CAR T cells infusion in solid tumors patients. [Срок оценки: 7 days, 14 days, 21 days, 30 days, 60 days, 90 days, 6 months and 12 months after B7H3-IL7Ra CAR-T cell infusion]

Вторичные конечные точки (1)

• The overall response rate of solid tumors [Срок оценки: 1, 3, 6, and 12 months after B7H3-IL7Ra CAR-T cell infusion]

Критерии участия

Критерии включения

• Participants must have B7-H3 positive solid tumor with measurable disease.

\- B7-H3 expression will be evaluated by standard immunohistochemistry (IHC) or flow cytometry using a previously obtained sample.

• Evidence of relapsed or refractory disease after standard first-line therapy
• Age 1 - 25 years
• Sex: Male or female
• Performance status: Lansky or Karnofsky score not less than 50
• Life expectancy not less than 12 weeks
• Normal organ function

• AST (SGOT) below 5 times the upper limit of normal (ULN)
• ALT (SGPT) below 5 times the upper limit of normal (ULN)
• Total bilirubin below 3 times the upper limit of normal (ULN)
• Creatinine below 5 times the upper limit of normal (ULN)
• SpO2 room air not less than 90%
• Prior therapy wash-out before planned leukapheresis

• Not less than 7 days post last chemotherapy/biologic therapy administration
• 3 half-lives or 30 days, whichever is shorter after the last dose of antitumor antibody therapy
• At least 30 days from most recent cellular infusion
• All systemically administered corticosteroid treatment therapy must be stable or decreasing within 1 week prior to enrollment with a maximum of 0.5 mg/kg/day dose of methylprednisolone. Corticosteroid physiologic replacement therapy is allowed
• Participants and/or legal guardians must have the ability to understand and willingness to sign a written informed consent and/or assent document

Критерии исключения

• Presence of greater than or equal to grade 3 cardiac dysfunction or symptomatic arrythmia requiring intervention
• Presence of primary immunodeficiency or bone marrow failure syndrome
• Presence of uncontrolled intercurrent illness including but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, pulmonary abnormalities, or psychiatric illness/social situations that would limit compliance with study requirements
• Pregnant or breastfeeding women were excluded from this study because CAR-T cell therapy may be associated with the potential for teratogenic or abortifacient effects. Women of childbearing potential must have a negative serum pregnancy test. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with CAR-T cells, breastfeeding should be discontinued. These potential risks may also apply to other agents used in this study. Participants of childbearing or child-fathering potential must be willing to practice birth control from the time of enrollment in this study and for four months after receiving CAR-T-cell infusion.
• Serologic status reflecting active HIV, hepatitis B or C infection. Participants who are positive for hepatitis B core antibody, hepatitis B surface antigen or hepatitis C antibody must have negative PCR prior to enrollment.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Не применимо

Модель

Одна группа

Маскирование

Открытое

Основная цель

Лечение

Центры проведения

Таиланд · 1 центр

• King Chulalongkorn Memorial Hospital — Bangkok

Идентификаторы

NCT: NCT06612645 · LV-CMD03-PST-P1-2024 · Chulalongkorn University

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗